Efficacy and safety of the long-acting β(2)-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

BACKGROUND: Olodaterol is a novel long-acting β(2)-agonist with proven ≥24-hour duration of action in preclinical and clinical studies. OBJECTIVE: This randomized, double-blind, placebo-controlled, parallel-group study evaluated the dose response of once-daily (QD) olodaterol based on bronchodilator...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Chron Obstruct Pulmon Dis
Main Authors: Ichinose, Masakazu, Takizawa, Ayako, Izumoto, Toshiyasu, Tadayasu, Yusuke, Hamilton, Alan L, Kunz, Christina, Fukuchi, Yoshinosuke
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2015
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4548739/
https://ncbi.nlm.nih.gov/pubmed/26316741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S86002
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares